TY - JOUR T1 - Esearch3D: Propagating gene expression in chromatin networks to illuminate active enhancers JF - bioRxiv DO - 10.1101/2022.08.04.502774 SP - 2022.08.04.502774 AU - Maninder Heer AU - Luca Giudice AU - Claudia Mengoni AU - Rosalba Giugno AU - Daniel Rico Y1 - 2022/01/01 UR - http://biorxiv.org/content/early/2022/08/06/2022.08.04.502774.abstract N2 - Most cell type-specific genes are regulated by the interaction of enhancers with their promoters. The identification of enhancers is not trivial as enhancers are diverse in their characteristics and dynamic in their interaction partners. Currently, enhancer-associated features such as histone modifications, co-activators or bi-directional transcription are used in lieu of any definitive and universal enhancer feature. We present Esearch3D, a new approach that leverages network theory approaches to identify active enhancers. Our work is based on the fact that enhancers act as a source of regulatory information to increase the rate of transcription of their target genes and that the flow of this information is mediated by the folding of chromatin in the three-dimensional (3D) nuclear space between the enhancer and the target gene promoter. Esearch3D reverse engineers this flow of information to calculate the likelihood of enhancer activity in intergenic regions by propagating the transcription levels of genes across 3D-genome networks. Regions predicted to have high enhancer activity are shown to be enriched in annotations indicative of enhancer activity. These include: enhancer-associated histone marks, bi-directional CAGE-seq, STARR-seq, P300 and RNA polymerase II ChIP-seq, and expression quantitative trait loci (eQTL). Esearch3D successfully leverages the relationship between chromatin architecture and global transcription and represents a novel approach to predict active enhancers and understand the complex underpinnings of regulatory networks. The method is available at: https://github.com/InfOmics/Esearch3D.Competing Interest StatementThe authors have declared no competing interest. ER -